NIDA CTN-0152: Evaluation of Tirzepatide As an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder: a Pragmatic, Multi-site, Double-blind, Randomized, Placebo-controlled Trial (TAB)

The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.

Start Date16 Sep 2025

Sponsor / Collaborator

University of Cincinnati (Ohio)

[+1]

ACTRN12624001278527 / Not yet recruitingPhase 3

Effect of tirzepatide on asthma control in obese asthmatics aged 16 years and over: A phase III randomised double blinded placebo control trial

Start Date02 Jun 2025

Sponsor / Collaborator

The University of Queensland

NCT06657209 / Not yet recruitingPhase 4IIT

Normal-weight Diabetes: Adipocyte-directed Therapy with Pioglitazone or Tirzepatide

This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD) and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.

Start Date15 Dec 2024

Sponsor / Collaborator

Stanford University

100 Clinical Results associated with Tirzepatide

100 Translational Medicine associated with Tirzepatide

100 Patents (Medical) associated with Tirzepatide

532

Literatures (Medical) associated with Tirzepatide

01 Jan 2025·Molecular Metabolism

Incretin-responsive human pancreatic adipose tissue organoids: A functional model for fatty pancreas research

Article

Author: Birkenfeld, A.L. ; Mihaljevic, Al ; Birkenfeld, Al ; Rahimi, G. ; Neuscheler, D. ; Jumpertz-von Schwartzenberg, R ; Neuscheler, D ; Strauss, O D ; Lorza-Gil, E. ; Sandforth, A ; Gerst, F. ; Sbierski-Kind, J. ; Müller, T D ; Müller, T.D. ; Ziegler, E. ; Kaufmann, B. ; Sandforth, L ; Rahimi, G ; Sandforth, L. ; Kansy, K ; Müller, Td ; Jumpertz-von Schwartzenberg, R. ; Mihaljevic, A L ; Sbierski-Kind, J ; Lorza-Gil, E ; Sancar, G ; Mihaljevic, A.L. ; Kansy, K. ; Sandforth, A. ; Birkenfeld, A L ; Katschke, M.-T. ; Strauss, O. ; Hartmann, D. ; Katschke, M-T ; Singer, S. ; Sancar, G. ; Hartmann, D ; Singer, S ; Gerst, F ; Kaufmann, B ; Ziegler, E

OBJECTIVE:

Infiltration of adipocytes into the pancreatic parenchyma has been linked to impaired insulin secretion in individuals with increased genetic risk of T2D and prediabetic conditions. However, the study of this ectopic fat depot has been limited by the lack of suitable in vitro models.

METHODS:

Here, we developed a novel 3D model of functionally mature human pancreatic adipose tissue organoids by aggregating human pancreatic adipose tissue-derived stromal vascular fraction (SVF) cells into organoids and differentiating them over 19 days.

RESULTS:

These organoids carry biological properties of the in situ pancreatic fat, presenting levels of adipogenic markers comparable to native pancreatic adipocytes and improved lipolytic and anti-lipolytic response compared to conventional 2D cultures. The organoids harbour a small population of immune cells, mimicking in vivo adipose environment. Furthermore, they express GIPR, allowing investigation of incretin effects in pancreatic fat. In accordance, GIP and the dual GLP1R/GIPR agonist tirzepatide stimulate lipolysis but had distinct effects on the expression of proinflammatory cytokines.

CONCLUSIONS:

This novel adipose organoid model is a valuable tool to study the metabolic impact of incretin signalling in pancreatic adipose tissue, revealing potential therapeutic targets of incretins beyond islets. The donor-specific metabolic memory of these organoids enables examination of the pancreatic fat-islet crosstalk in a donor-related metabolic context.

01 Jan 2025·Obesity Reviews

Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity

Review

Author: Christensen, Sandra M. ; Mechanick, Jeffrey I. ; Prado, Carla M. ; Heymsfield, Steven B. ; Li, Zhaoping ; Hamdy, Osama ; Butsch, W. Scott

Summary:

The rapid and widespread clinical adoption of highly effective incretin‐mimetic drugs (IMDs), particularly semaglutide and tirzepatide, for the treatment of obesity has outpaced the updating of clinical practice guidelines. Consequently, many patients may be at risk for adverse effects and uncertain long‐term outcomes related to the use of these drugs. Of emerging concern is the loss of skeletal muscle mass and function that can accompany rapid substantial weight reduction; such losses can lead to reduced functional and metabolic health, weight cycling, compromised quality of life, and other adverse outcomes. Available evidence suggests that clinical trial participants receiving IMDs for the treatment of obesity lost 10% or more of their muscle mass during the 68‐ to 72‐week interventions, approximately equivalent to 20 years of age‐related muscle loss. The ability to maintain muscle mass during caloric restriction‐induced weight reduction is influenced by two key factors: nutrition and physical exercise. Nutrition therapy should ensure adequate intake and absorption of high‐quality protein and micronutrients, which may require the use of oral nutritional supplements. Additionally, concurrent physical activity, especially resistance training, has been shown to effectively minimize loss of muscle mass and function during weight reduction therapy. All patients receiving IMDs for obesity should participate in comprehensive treatment programs emphasizing adequate protein and micronutrient intakes, as well as resistance training, to preserve muscle mass and function, maximize the benefit of IMD therapy, and minimize potential risks.

01 Jan 2025·JOURNAL OF AFFECTIVE DISORDERS

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)

Article

Author: Le, Gia Han ; Mansur, Rodrigo B. ; Rhee, Taeho Greg ; Rosenblat, Joshua D. ; McIntyre, Roger S ; Ho, Roger ; McIntyre, Roger S. ; Rosenblat, Joshua D ; Kwan, Angela T.H. ; Teopiz, Kayla M ; Wong, Sabrina ; Cao, Bing ; Kwan, Angela T H ; Teopiz, Kayla ; Mansur, Rodrigo B

INTRODUCTION:

Reports of suicidality associated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been reported to the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). We previously reported an increased reporting odds ratio (ROR) of some measures of suicidality with semaglutide and liraglutide using the FDA Adverse Event Reporting System (FAERS). Notwithstanding the increased ROR, causality between GLP-1 RAs exposure and any aspect of suicidality is not established.

RESEARCH DESIGN AND METHODS:

The analysis herein aims to extend a previous analysis of the FAERS by evaluating the ROR for suicidality reported to the World Health Organization (WHO) Pharmacovigilance Database (VigiBase). We aimed to characterize the ROR of suicidality associated with GLP-1 RAs, as extrapolated from spontaneous reports. As per our previous report, the ROR was considered significant when the lower limit of the 95 % confidence (CI) was >1.0.

RESULTS:

We searched VigiBase reports from inception to January 2024. The RORs for suicidal ideation were significantly increased for semaglutide (5.82), liraglutide (4.03) and tirzepatide (2.25). For "depression/suicidal", the ROR was significantly increased for semaglutide (14.74) and liraglutide (5.86); and for suicidal behaviour, the ROR was significantly increased for semaglutide (6.52) and liraglutide (3.90). However, for suicide attempts, the ROR was significantly decreased for semaglutide (0.11), dulaglutide (0.075), exenatide (0.047) and liraglutide (0.15). For completed suicide, the ROR was also significantly decreased for semaglutide (0.01), dulaglutide (0.003), exenatide (0.002) and liraglutide (0.008).

CONCLUSION:

Unlike our previous report with FAERS, a mixed pattern of ROR emerged in the WHO VigiBase with respect to suicidality and exposure to select GLP-RAs. Causation between GLP-1 RA exposure and suicidality (either increased or decreased) cannot be ascertained from ROR data.

958

News (Medical) associated with Tirzepatide

07 Dec 2024

·endpts.com

Lilly beats Novo in weight loss; Apogee plots Dupixent challenge; Biosecure compromise coming?; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here . We have a group of reporters — myself included — in San Diego this weekend to cover all the latest from this year’s ASH conference. Can’t make it? Sign up for our virtual ASH event on Tuesday recapping some of the biggest headlines. — Max Gelman Lilly beats Novo in first head-to-head weight loss study Eli Lilly said its weight loss drug Zepbound bested Novo Nordisk’s rival Wegovy in a Phase 3 head-to-head trial, providing the clearest evidence yet that it may have an edge over its competitor. Lilly launched the randomized, controlled trial, SURMOUNT-5, more than a year and a half ago in April 2023. On Wednesday, the company said patients given Zepbound lost 20.2% of their body weight on average by week 72, compared to 13.7% for Wegovy. Apogee plots Dupixent head-to-head In other head-to-head news, I&I drugmaker Apogee plans to pit its lead drug APG777 against Sanofi and Regeneron’s blockbuster Dupixent in a trial starting next year. APG777 will be paired in a co-formulation with Apogee’s OX40L-targeting mAb called APG990 for patients with moderate-to-severe atopic dermatitis. The company thinks APG777, an IL-13 targeting monoclonal antibody, can eventually generate more than $10 billion in sales. “Everyone says, ‘Oh, we’re going to be better. It should be better,’” CEO Michael Henderson said. “No one ever actually runs that head-to-head study.” Biosecure compromise in the works? Lawmakers are considering a compromise to the Biosecure Act that would add an executive branch review to the process, giving the White House or federal agencies final say on the enactment of restrictions. A version of the bill previously passed by the House of Representatives would directly force biopharmas to eventually cut ties with Chinese companies named in the legislation. However, the situation appears to be highly fluid, proposals may change further and any potential deal could fall apart in Congress’ rush to finish its work before the session ends. Novartis pays $1B upfront for Huntington’s drug In its latest deal, Novartis has agreed to pay $1 billion upfront for PTC Therapeutics’ Phase 2 Huntington’s drug and “related molecules.” The deal could be worth another $1.9 billion in biobucks, the companies announced on Monday. Novartis was previously working on its own Huntington’s disease medicine, but ended the Phase 2 program last year due to neurotoxicity signals. Healthcare execs weigh security risks after United Healthcare shooting The shooting of United Healthcare CEO Brian Thompson has prompted other healthcare companies to rethink the measures they take to keep their top brass safe. CEOs often have protective details, and there have been prior cases of top executives who have faced harassment and threats. But this week’s shooting was an outlier, and actual violence against top executives is almost unheard of. It’s also put a spotlight on security measures for next month’s JP Morgan Healthcare Conference — the biggest pharma event of the year. SPOTLIGHT As 23andMe struggles, another genetic testing company bets on drug discovery Eliav Barr defends Merck’s LaNova deal, but cautions VEGF bispecifics have yet to deliver mature data Lilly continues to expand its empire of GLP-1 factories with new $3B buildout MORE IN DEALS MORE IN R&D MORE IN MANUFACTURING MORE IN FINANCING MORE IN PHARMA MORE IN FDA+ MORE IN HEALTH TECH

Phase 3Phase 2

07 Dec 2024

·www.biopharmadive.com

BioAge shares tumble after decision to halt obesity drug study

Dive Brief:BioAge Labs said it is terminating a mid-stage study of its obesity drug candidate azelaprag in combination with Eli Lillys tirzepatide due to safety concerns, causing its share price to slide by three-quarters in after-hours trading Friday.Eleven people who received azelaprag in STRIDES, BioAges Phase 2 study, showed elevated levels of liver enzymes that can warn of potential organ damage. As a result, the company is discontinuing dosing and halting further enrollment.The San Francisco Bay Area company raised $170 million in February and banked a $198 million initial public offering in September to fund its ambitious foray into metabolic drugs, not long after it pivoted from making treatments for age-related diseases.Dive Insight:Study researchers spotted the spike in liver enzymes, or liver transaminitis, among people who received BioAges drug either as monotherapy or in combination with tirzepatide, which Lilly sells as Zepbound. No participants who were treated only with Zepbound experienced liver transaminitis.The increase in enzyme counts was not associated with any clinically significant symptoms, BioAge said. The company plans to share an update in early 2025 on its plans for azelaprags development.We made the difficult decision to discontinue the STRIDES Phase 2 study of azelaprag because it became clear that the emerging safety profile of the current doses tested is not consistent with our goal of a best-in-class oral obesity therapy, Kristen Fortney, BioAges CEO, said in a statement.Azelaprag is designed to mimic a peptide called apelin, which is excreted in response to physical exercise. Preclinical data from BioAge seemed to show that combining azelaprag with incretin drugs could boost the effects of the latter, helping patients shed weight but preserve muscle.The company launched the study, which was set to enroll 220 people with obesity ages 55 and older, in July. At the time, Fortney said the drug could be a powerful pharmacological parallel to the exercise and diet interventions that form the foundation of obesity management.BioAge had originally planned to launch a Phase 2 clinical trial with semaglutide, or Novo Nordisks Wegovy, in the first half of 2025.With azelaprag, BioAge was targeting a niche that venture investors and pharmaceutical companies alike have been trying to fill as Wegovy and Zepbound have gained popularity: preserving lean muscle mass while still shedding weight. The company licensed azelaprag from Amgen in 2021 with plans to develop it to combat muscle aging.Over the past two years, several companies have shared plans to make experimental weight loss drugs designed to do the same thing, including Scholar Rock, Biohaven Pharmaceutical and Regeneron. Venture investors have also bought in, backing early startups such as SixPeaks Bio.Shares in BioAge, which closed Friday at just over $20 apiece, plunged by two-thirds in post-market trading Friday.The company plans to file an application to advance another program it's developing for central nervous system targets in the second half of 2025. '

Phase 2

06 Dec 2024

·www.globenewswire.com

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share updated plans for azelaprag in Q1 2025 In parallel to evaluating azelaprag, Company will continue to advance earlier platform-derived programs, including IND submission for CNS penetrant NLRP3 inhibitor anticipated in the second half of 2025 RICHMOND, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company has made the decision to discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag as monotherapy and in combination with tirzepatide after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag. No transaminase elevations were observed in the tirzepatide only treatment group. “Patient safety is our top priority in the conduct of our clinical studies,” said Kristen Fortney, PhD, CEO and co-founder of BioAge. “We made the difficult decision to discontinue the STRIDES Phase 2 study of azelaprag because it became clear that the emerging safety profile of the current doses tested is not consistent with our goal of a best-in-class oral obesity therapy. While this outcome is a significant disappointment, we remain encouraged by azelaprag’s promising preclinical and Ph1b efficacy profile. We remain committed to our focus on developing therapies for metabolic aging. In parallel to assessing the next steps for the azelaprag program, we will continue to advance our NLRP3 inhibitor program as well as additional research programs with novel mechanisms emerging from our platform.” STRIDES is a randomized, double-blind, placebo-controlled Phase 2 clinical trial of azelaprag as monotherapy and in combination with tirzepatide that planned to enroll approximately 220 individuals with obesity aged 55 years and older (link). The trial was designed to evaluate the efficacy as measured by body weight reduction and other outcomes, safety, and tolerability of two oral doses of azelaprag (300 mg, once or twice daily) in combination with tirzepatide (5 mg subcutaneous injection once weekly). An azelaprag monotherapy arm was included to provide additional safety information. Of 204 subjects enrolled in STRIDES as of today, 11 subjects in the azelaprag treatment groups were observed to have transaminase elevations with no clinically significant symptoms. Dosing of all subjects will be discontinued, and no additional subjects will be enrolled. Clinical follow-up of enrolled subjects will continue off drug. The Company intends to further analyze available STRIDES clinical data from all enrolled subjects. The Company has notified all study investigators and regulatory authorities including the U.S. Food and Drug Administration (FDA) of the Company’s decision to discontinue enrollment. The Company intends to share updated plans for azelaprag in Q1 2025. BioAge continues to advance its pipeline of therapeutic candidates targeting the biology of aging to treat metabolic diseases. The Company's novel class of brain-penetrant NLRP3 inhibitors, which have demonstrated high potency and a novel binding site, are progressing toward IND submission, anticipated in the second half of 2025. The NLRP3 inhibitor program targets neuroinflammation, which is linked to both metabolic and neurodegenerative diseases. In addition, BioAge is advancing multiple targets derived from its proprietary discovery platform, which analyzes molecular data spanning over 50 years of human aging trajectories. About BioAge Labs, Inc.BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead product candidate, azelaprag, is an orally available small molecule agonist of APJ that was observed to promote metabolism and prevent muscle atrophy on bed rest in a Phase 1b clinical trial. BioAge is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. BioAge’s preclinical programs, based on novel insights from the company’s discovery platform built on human longevity data, address key pathways in metabolic aging. Forward-looking statementsThis press release contains “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our plans to develop and commercialize our product candidates, our business strategy, results of our ongoing or planned clinical trials, the timing of any future updates to our programs and the clinical utility of our product candidates. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize our product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; failure to comply with legal and regulatory requirements; risks relating to access to capital and credit markets; and the other risks and uncertainties that are detailed under the heading “Risk Factors” included in BioAge’s Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on November 7, 2024, and other filings with the SEC filed from time to time. BioAge undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. ContactsPR: Chris Patil, media@bioagelabs.com IR: Elena Liapounova, ir@bioagelabs.com Partnering: partnering@bioagelabs.com Web: https://bioagelabs.com

Phase 2Phase 1

100 Deals associated with Tirzepatide

External Link

KEGG	Wiki	ATC	Drug Bank
D11360	Tirzepatide	-	DB15171

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	US	Eli Lilly & Co.	08 Nov 2023
Overweight	US	Eli Lilly & Co.	08 Nov 2023
Weight Gain	AU	Eli Lilly Australia Pty Ltd.	23 Dec 2022
Diabetes Mellitus, Type 2	US	Eli Lilly & Co.	13 May 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart failure with normal ejection fraction	NDA/BLA	CN	Eli Lilly & Co.	22 Nov 2024
Obesity Hypoventilation Syndrome	NDA/BLA	CN	Eli Lilly & Co.	15 Sep 2024
Sleep Apnea, Obstructive	NDA/BLA	US	Eli Lilly & Co.	21 Jun 2024
Plaque psoriasis	Phase 3	US	Eli Lilly & Co.	30 Sep 2024
Plaque psoriasis	Phase 3	PR	Eli Lilly & Co.	30 Sep 2024
Arthritis, Psoriatic	Phase 3	US	Eli Lilly & Co.	24 Sep 2024
Arthritis, Psoriatic	Phase 3	PR	Eli Lilly & Co.	24 Sep 2024
Cardiovascular Diseases	Phase 3	US	Eli Lilly & Co.	29 May 2020
Cardiovascular Diseases	Phase 3	US	Lilly Asia Shanghai Representative Office	29 May 2020
Cardiovascular Diseases	Phase 3	AR	Eli Lilly & Co.	29 May 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05822830 (SURMOUNT-5, Company_Website) Manual	Phase 3	Obesity	751	Zepbound (tirzepatide)	rfztsmyiju(bgaucpwjzv) = csztxwghea llgpmvrxxr (slbtybvigz ) View more	Superior	04 Dec 2024
				Wegovy (semaglutide)	rfztsmyiju(bgaucpwjzv) = qjxhwhmqgb llgpmvrxxr (slbtybvigz ) View more
NCT04847557 (SUMMIT, Pubmed) Manual	Phase 3	Heart failure with normal ejection fraction \| Obesity	731	Tirzepatide	rbznzfhpaj(imktbsaonv) = inhlpqabzb iisxifgouh (leduczwtrh ) View more	Positive	16 Nov 2024
				Placebo	rbznzfhpaj(imktbsaonv) = qnvjfnlwwj iisxifgouh (leduczwtrh ) View more
NCT04847557 (SUMMIT, Pubmed \| N Engl J Med)	Phase 3	Heart failure with normal ejection fraction	731	Tirzepatide	qrlnulvanw(keirxvcilr) = mainly gastrointestinal, leading to discontinuation of the trial drug occurred in 23 patients (6.3%) in the tirzepatide group and in 5 patients (1.4%) in the placebo group ypitwrodbn (hzysiypcii )	Positive	16 Nov 2024
				Placebo
NCT04184622 (SURMOUNT-1, Literature) Manual	Phase 3	Diabetes Mellitus \| Obesity	2,539	Tirzepatide	ynldbdiffz(hqxamqpqqb) = btqmaadzim zznjtlbkgx (gfpjjockpg ) View more	Positive	13 Nov 2024
				Tirzepatide 5 mg	ynldbdiffz(hqxamqpqqb) = egejraiosd zznjtlbkgx (gfpjjockpg ) View more
Pubmed \| N Engl J Med	Not Applicable	Diabetes Mellitus \| Obesity	-	Tirzepatide 5 mg	sgqfvpfddc(tereubbjpk) = most common adverse events were gastrointestinal, most of which were mild to moderate in severity and occurred primarily during the dose-escalation period in the first 20 weeks of the trial mbbknwkzym (gljrobxvfa )	-	13 Nov 2024
				Tirzepatide 10 mg
NCT03730662 \| NCT03954834 \| NCT04039503 \| NCT03882970 \| NCT03987919 (SURPASS-1 to -5, Pubmed \| Diabetes Ther)	Phase 3	Diabetes Mellitus, Type 2	-	Tirzepatide 5 mg	anpckeofbu(sicwgngizr) = The most common treatment-emergent adverse events were gastrointestinal in nature xbvzytepcm (bvlzyzaoox )	Positive	12 Nov 2024
				Tirzepatide 10 mg
Drugs Manual	Not Applicable	Diabetes Mellitus, Type 1	100	Ozempic	qdwndfzkjs(tyeldanjws) = qdgtfvqgzi jqjilromna (zpzpviddlr ) View more	Positive	13 Sep 2024
				Mounjaro	qdwndfzkjs(tyeldanjws) = ivqpjcppoa jqjilromna (zpzpviddlr ) View more
NCT04184622 (SURMOUNT-1, Company_Website) Manual	Phase 3	Prediabetic State \| Overweight \| Obesity	1,032	Tirzepatide 5 mg	zcszujwbsd(xlhmipnrei) = rtlwoqfrbb ohqbgunpfk (ezuovbhggo )	Positive	20 Aug 2024
				Tirzepatide 10 mg	zcszujwbsd(xlhmipnrei) = nwrznzcsvg ohqbgunpfk (ezuovbhggo )
NCT04847557 (SUMMIT, Company_Website) Manual	Phase 3	Heart failure with normal ejection fraction \| Obesity	731	Tirzepatide	fdgbnwocnv(akjapwkivl) = pxprfbmjsl hqmkeopawg (kvrmvelico ) View more	Positive	01 Aug 2024
				Placebo	hgdpjqmztz(pdbeefommp) = zkqnuektgt zoyaaodogi (jdbquybrus ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis